A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Primary Objectives:
- To determine the safety, toxicity and the maximum tolerated dose (MTD) of intravenous
STA-5312 when administered weekly (3 of 4 weeks) to subjects with advanced or metastatic
solid tumors.
- To determine the pharmacokinetics of STA-5312.
Secondary Objective:
• To assess antitumor activity of STA-5312 administration.